Fennec Pharmaceuticals Inc.
Join Class Action »
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) from February 11, 2020 through August 10, 2020 (the “Class Period”). The lawsuit seeks to recover damages for Fennec Pharmaceuticals Inc. investors under the federal securities laws.
If you bought Fennec Pharmaceuticals Inc. securities between February 11, 2020 through August 10, 2020, and would like to join the action, please click “Join This Class Action,” above.
SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against Fennec Pharmaceuticals Inc. – FENC
New York, N.Y., September 16, 2020. Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between February 11, 2020 and August 10, 2020, inclusive (the “Class Period”).
To join the FENC class action, go to http://zhanginvestorlaw.com/cases/fennec-pharmaceuticals-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email email@example.com for information on the class action.
Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.
According to the lawsuit, throughout the Class Period (1) the manufacturing facilities for PEDMARK, the Company’s sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/fennec-pharmaceuticals-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at firstname.lastname@example.org.
Zhang Investor Law represents investors worldwide.